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Alk3 controls nephron number
Di Giovanni et al., Development 2011; 138: 2717–2727; doi:10.1242/
dev.059030
The number of nephrons in the kidney is a critical determinant 
of this organ’s function and has profound influence on the vol-
ume of the extracellular fluid and cardiovascular homeostasis. 
Kidney organogenesis and nephron development result from the 
reciprocal signaling between the ureteric bud and the metane-
phric mesenchyme. Both these embryonic kidney domains derive 
from a population of cells from the intermediate mesoderm that 
expresses odd-skipped-related 1 (Osr1). It was recently found 
that the constitutive active activin-like kinase 3 (ALK3) recep-
tor regulates expression of Osr1 in the intermediate mesoderm 
of the chick embryo. Accordingly, Di Giovanni et al. examined 
the role of ALK3 signaling in murine kidney development. They 
conditionally inactivated Alk3 in intermediate mesoderm pro-
genitors (Alk3IMP-null) using an Alk3loxP allele and Cre recombi-
nase directed by the retinoic acid receptor-b isoform 2 (Rarb2) 
promoter. They found (Figure) that at 1 month of age, after com-
pletion of nephrogenesis, renal architecture was normal but the 
mutants had fewer glomeruli, suggesting a defect in nephrogen-
esis. Analysis of newborn mice showed normal renal histoar-
chitecture but kidney area reduced by about 40% in Alk3IMP-null 
mice when compared with wild type and by 35% when compared 
with Alk3+/− littermates, although embryo sizes in these animals 
were no different. Quantification of nephrons revealed a signifi-
cant decrease in Alk3IMP-null but not in Alk3+/− mice. The authors 
also found that at the start of kidney development, expression 
of Osr1 was reduced in the Alk3IMP-null mice. More importantly, 
expression of both SIX2 (needed for maintenance of the self-
renewing nephrogenic progenitor population) and the Foxd1 
domain (marker of the stroma compartment) was reduced in 
mutants. Thus, Alk3 deficiency in the metanephric mesenchyme 
causes simple renal hypoplasia defined as decreased kidney size 
and nephron number but normal tissue patterning. Of extreme 
interest is that these mutants had a lower number of nephrons 
without delayed nephrogenesis, abnormal nephron differentia-
tion, reduced cell proliferation, or increased apoptosis, as found 
in several genetic mouse models with hypoplastic kidneys. 
Juan Oliver
The effects of lowering LDL 
cholesterol with simvastatin plus 
ezetimibe in patients with chronic 
kidney disease: a randomized 
placebo-controlled trial
Baigent et al., Lancet 2011; 377: 2181–2192; doi:10.1016/S0140-
6736(11)60739-3
Chronic kidney disease (CKD) is associated with an increased risk 
of cardiovascular disease, but little is known about its prevention. 
Lowering low-density lipoprotein (LDL) cholesterol with statin regi-
mens reduces the risk of myocardial infarction, ischemic stroke, and 
the need for coronary revascularization in people without kidney 
disease, but its effects in people with moderate to severe kidney 
disease are uncertain. The Study of Heart and Renal Protection 
(SHARP) aimed to assess the efficacy and safety of the combination 
of simvastatin plus ezetimibe in a randomized double-blind trial 
that included 9270 patients with CKD (3023 on dialysis and 6247 
not) with no known history of myocardial infarction or coronary 
revascularization. Patients were randomly assigned to 20 mg sim-
vastatin plus 10 mg ezetimibe daily versus matching placebo. The 
key prespecified outcome was first major atherosclerotic event (non-
fatal myocardial infarction or coronary death, non-hemorrhagic 
stroke, or any arterial revascularization procedure). All analyses 
were by intention to treat. The researchers assigned 4650 patients 
to receive simvastatin plus ezetimibe and 4620 to receive placebo. 
Allocation to simvastatin plus ezetimibe yielded an average LDL 
cholesterol difference of 0.85 mmol/l (standard error 0.02, with 
about two-thirds compliance) during a median follow-up of 4.9 
years and produced a 17% proportional reduction in major athero-
sclerotic events (526 (11.3%) simvastatin plus ezetimibe versus 619 
(13.4%) placebo; rate ratio (RR) 0.83, 95% confidence interval (CI) 
0.74–0.94). After weighting for subgroup-specific reductions in 
LDL cholesterol, there was no good evidence that the proportional 
effects on major atherosclerotic events differed from the summary 
rate ratio in any subgroup examined, and, in particular, they were 
similar in patients on dialysis and those who were not. The excess 
risk of myopathy was only two per 10,000 patients per year of treat-
ment with this combination. There was no evidence of excess risks 
of hepatitis, gallstones, or cancer, and there was no significant excess 
of death from any nonvascular cause.
Given the absence of any benefit, compared with placebo, for non-
fatal myocardial infarction or death from coronary heart disease, 
one must ask whether the combination of a statin with ezetimibe (an 
Renal hypoplasia in Alk3IMP-null mice. (a, b) Renal histology at 1 month 
of age. The number of glomeruli (arrowheads) was greater in control (a) 
than in Alk3IMP-null mice (b). (c–e) Cross-sectional area in wild-type (c) and 
embryonic day 18.5 Alk3+/− mice (d) was, respectively, comparable to and 
larger than that in Alk3IMP-null mice (e).
D
i G
io
va
nn
i e
t a
l./
D
ev
el
op
m
en
t
442   Kidney International (2011) 80
journal  c lub
inhibitor of gastrointestinal absorption of cholesterol), known for 
numerous side effects and higher cost of treatment, represents any 
progress in the treatment of cardiovascular diseases in CKD.
Marc De Broe
Fibroblast growth factor 23 and risks 
of mortality and end-stage renal 
disease in patients with chronic 
kidney disease
Isakova et al., JAMA 2011; 305: 2432–2439; doi:10.1001/jama.2011.826
The associations between mortality and disorders of bone and 
mineral metabolism, as well as the role of fibroblast growth factor 
23 (FGF-23) in that pathway, are well recognized among people 
with end-stage renal disease (ESRD). Isakova et al. examined these 
associations among people with CKD. FGF-23 levels were measured 
from stored serum samples from patients enrolled in the Chronic 
Renal Insufficiency Cohort study. Three thousand six hundred 
twelve individuals with glomerular filtration rate (GFR) between 
20 and 70 ml/min were recruited into this observational cohort 
and followed for the outcomes associated with CKD. The cohort 
has a broad representation of patients with CKD, oversampling for 
minorities and excluding patients with human immunodeficiency 
virus and polycystic kidney disease. FGF-23 levels were more than 
threefold higher in this cohort than in a cohort with a low prevalence 
of kidney disease in spite of only minimal concurrent phosphorus 
elevation (mean serum phosphorus 3.7 mg/dl). Similar trends were 
seen when cohorts with increasing levels of serum FGF-23 were 
compared. Strata of patients with greater levels of FGF-23 were com-
posed of greater proportions of patients with more comorbidities, 
including hypertension, diabetes mellitus, coronary artery disease, 
congestive heart failure, stroke, peripheral vascular disease, and cur-
rent use of tobacco. Although the values were still within normal 
limits, participants in increasing quartiles also demonstrated a trend 
toward increasing levels of serum phosphorus, from 3.4 mg/dl in 
the lowest quartile to 4.1 in the highest. The rates of progression to 
ESRD and death increased among quartiles with increasing FGF-23 
levels. The association between FGF-23 and death maintained its 
significance when controlled for clinical and demographic param-
eters including case mix, medical history, laboratory parameters, 
and medication. As compared with participants in the lowest quar-
tile, the risk of mortality was 1.3, 2.0, and 3.0 in increasing quartiles. 
Similar relationships were demonstrated when FGF-23 quartiles 
were compared with respect to the risk of ESRD. However, the trend 
seen in univariate analyses dissipated when controlled for laboratory 
parameters to include estimated GFR.
This analysis therefore suggests that the mechanisms of altered 
bone and mineral metabolism that portend a greater risk of 
morbidity and mortality in patients with ESRD have a similar 
relationship with outcomes among people with CKD. Further, it 
suggests that FGF-23 may play a role as an intermediate marker 
and goal of care. 
Lynda Szczech
Aurora A kinase in polycystic  
kidney disease
Plotnikova et al., J Cell Biol 2011; 193: 1021–1032; doi:10.1083/jcb.201012061
The Aurora A (AurA) kinase is involved in the regulation of 
the cell’s entry into and passage through mitosis. It functions as 
an oncogene when exogenously expressed in cell lines, and it 
was found overexpressed in many tumors, including renal-cell 
carcin omas. AurA also has non-mitotic actions, among which 
is promoting cilia disassembly and ciliary reabsorption. AurA is 
expressed in normal kidneys, and, interestingly, elevated levels of 
intra cellular calcium activate its kinase activity. As autosomal dom-
inant polycystic kidney disease (PKD) induces changes in calcium 
signaling, Plotnikova et al. examined whether changes in AurA 
expression or activity might be involved in development of renal 
cysts. They found that in normal kidneys AurA was most abun-
dant in cells of the proximal and particularly the distal convoluted 
tubules and in the collecting ducts. Examination of renal cysts 
derived from eight patients with PKD showed prominent AurA 
staining within the epithelial cells lining the cyst but not the fibrotic 
tissue; staining was particularly noticeable in small and mid-sized 
cysts and in areas of hyperproliferative epithelial cells adjacent 
to cysts and was accompanied by a strong T288-phAurA signal, 
indicating kinase activation (Figure). The polycystin 2 (PC2) Ca2+ 
channel is abundant and active in kidney cells, and PC2 function 
in PKD is reduced because of direct mutation or mutation of its 
upstream partner PC1, resulting in abnormal Ca2+ homeostasis. 
Interestingly, the authors then found that AurA negatively regu-
lated the basal Ca2+ level of renal cells and PC2-dependent Ca2+ 
release; AurA bound and phosphorylated PC2, and inhibition of 
AurA by small-molecule inhibitors enhanced PC2 activity and 
increased the magnitude of endoplasmic reticulum Ca2+ release. 
In sum, AurA binds, phosphorylates, and reduces the activity of 
PC2 and thus limits the amplitude of Ca2+ release.
The findings that AurA is abundant and frequently active in nor-
mal kidney tissue and abnormally expressed in PKD-associated 
renal cysts, together with the finding that it interacts with PC2, 
provide strong evidence that changes in AurA function may be 
relevant to the pathogenesis of PKD.
Juan Oliver 
Abnormal AurA expression and activity in renal cysts. Immuno-
histochemical detection of AurA and phAurA in renal cysts from 
PKD patients. Epithelial cells lining cysts and cyst-associated areas of 
hyperproliferative epithelial cells, but not cyst-associated fibrotic tissue, 
consistently demonstrate strong staining. phAurA, phospho-AurA.
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